BrickBio, a Boston, MA-based biotechnology company focused on developing precision biologics using an expanded genetic code, received an investment from Samsung Ventures.
The amount of the investment – made by Samsung Life Science Fund, created jointly between Samsung Biologics (KRX: 207940.KS), Samsung Bioepis, and Samsung C&T (KRX: 028260.KS), and managed by Samsung Ventures, was not disclosed.
The company intends to use the funds to support further development and advancement of its protein engineering technology and preclinical assets.
Led by CEO John Boyce, BrickBio is a biotechnology company providing a site-specific and site-selective platform, which spans prokaryotic and eukaryotic expression systems, enabling the development of unique biologics and protein therapeutics with enhanced characteristics, including improvements to half-life, dosage and efficacy. With a toolkit of bioconjugation handles, it can optimize any conjugate. The company is expanding its therapeutic programs, including ADCs, bispecific conjugates and novel scaffolds.
FinSMEs
19/03/2024